Literature DB >> 15578982

Therapeutic targeting of interactions between Nef and host cell proteins.

Kalle Saksela1.   

Abstract

Nef is a viral pathogenicity factor that has an important role in disease progression associated with HIV infection. Yet, no antiviral drugs capable of inhibiting of Nef are available or in clinical trials today. In this review the challenges and potential involved in pharmaceutical targeting of Nef are discussed in light of current understanding of the molecular mechanisms of Nef action, with a special emphasis on effector functions of Nef that are mediated via SH3 domain-directed interactions with host cell proteins.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15578982     DOI: 10.2174/1568008043339776

Source DB:  PubMed          Journal:  Curr Drug Targets Immune Endocr Metabol Disord        ISSN: 1568-0088


  5 in total

1.  Protein protein interaction inhibition (2P2I) combining high throughput and virtual screening: Application to the HIV-1 Nef protein.

Authors:  Stéphane Betzi; Audrey Restouin; Sandrine Opi; Stefan T Arold; Isabelle Parrot; Françoise Guerlesquin; Xavier Morelli; Yves Collette
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-27       Impact factor: 11.205

2.  Effects of HIV-1 Nef on human N-myristoyltransferase 1.

Authors:  Christopher R Morgan; Brian V Miglionico; John R Engen
Journal:  Biochemistry       Date:  2011-03-30       Impact factor: 3.162

3.  Intra- and intersubtype alternative Pak2-activating structural motifs of human immunodeficiency virus type 1 Nef.

Authors:  Eduardo O'Neill; Laura L Baugh; Vladimir A Novitsky; Myron E Essex; J Victor Garcia
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

4.  Immune selection in vitro reveals human immunodeficiency virus type 1 Nef sequence motifs important for its immune evasion function in vivo.

Authors:  Martha J Lewis; Patricia Lee; Hwee L Ng; Otto O Yang
Journal:  J Virol       Date:  2012-05-02       Impact factor: 5.103

5.  Nef does not contribute to replication differences between R5 pre-AIDS and AIDS HIV-1 clones from patient ACH142.

Authors:  Kevin C Olivieri; Robert M Scoggins; Brooks Broderick; Maria L C Powell; Melissa A Alexander; Marie-Louise Hammarskjöld; David Rekosh; David Camerini
Journal:  Retrovirology       Date:  2008-05-29       Impact factor: 4.602

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.